Is there any clinical or laboratory predictive factor for cetuximab-induced skin toxicity?

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics. In: CA Cancer J Clin.n/a(n/a). 2020.
   Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3;350(23):2335–2342.
   PubMed Web of Science ®Google Scholar
• Stintzing S, Modest DP, Rossius L, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol. 2016 oct 1;17(10):1426–1434.
   PubMed Web of Science ®Google Scholar
• Qin S, Li J, Wang L, et al. Efficacy and tolerability of first-line cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX-4) versus FOLFOX-4 in patients with ras wild-type metastatic colorectal cancer: the open-label, randomized, phase III TAILOR trial. J clin oncol. 2018;36(30):3031–3039.
   PubMed Web of Science ®Google Scholar
• Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol. 2014 Jul;25(7):1346–1355.
   PubMed Web of Science ®Google Scholar
• Li J, Yan H. Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials. Cancer Chemother Pharmacol. 2018 Oct;82(4):571–583.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–1075.
   PubMed Web of Science ®Google Scholar
• EudraVigilance database. [cited 2020 Dec 17]. Available from: https://bi.ema.europa.eu/analyticsSOAP/saw.dll?PortalPages
   Google Scholar
• Joshi SS, Ortiz S, Witherspoon JN, et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer. 2010;116(16):3916–3923.
   PubMed Web of Science ®Google Scholar
• Boone SL, Rademaker A, Liu D, et al. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology. 2007;72(3–4):152–159.
   PubMed Web of Science ®Google Scholar
• Holch JW, Held S, Stintzing S, et al. Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306). Ann Oncol. 2020 Jan;31(1):72–78.
   PubMed Web of Science ®Google Scholar
• Bar-Sela G, Avgush S, Kaidar-Person O, et al. Acne during adolescence did not predict skin rash reaction to cetuximab. Anticancer Drugs. 2016;27(10):1033–1037.
   PubMed Web of Science ®Google Scholar
• Jatoi A, Green EM, Rowland JKM, et al. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology. 2009;77(2):120–123.
   PubMed Web of Science ®Google Scholar
• Hichert V, Scholl C, Steffens M, et al. Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash. Oncotarget. 2017 May 23;8(21):35193–35204.
   PubMedGoogle Scholar
• Takahashi N, Yamada Y, Furuta K, et al. Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer. Cancer Sci. 2015 May;106(5):604–610.
   PubMed Web of Science ®Google Scholar
• Graziano F, Ruzzo A, Loupakis F, et al. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol. 2008 Mar 20;26(9):1427–1434.
   PubMed Web of Science ®Google Scholar
• Vallbohmer D, Zhang W, Gordon M, et al. Molecular determinants of cetuximab efficacy. J Clin Oncol. 2005 May 20;23(15):3536–3544.
   PubMed Web of Science ®Google Scholar
• Kubo A, Hashimoto H, Takahashi N, et al. Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer. World J Gastroenterol. 2016 Jan 14;22(2):887–894.
   PubMed Web of Science ®Google Scholar
• Mizuno H, Yuasa N, Takeuchi E, et al. Blood cell markers that can predict the long-term outcomes of patients with colorectal cancer. PloS One. 2019;14(8):e0220579.
   PubMed Web of Science ®Google Scholar
• Chen N, Li W, Huang K, et al. Increased platelet-lymphocyte ratio closely relates to inferior clinical features and worse long-term survival in both resected and metastatic colorectal cancer: an updated systematic review and meta-analysis of 24 studies. Oncotarget. 2017 May 9;8(19):32356–32369.
   PubMedGoogle Scholar
• Mb Es A, Greene FL. et al. AJCC Cancer Staging Manual. 8th. Springer International Publishing 2017
   Google Scholar
• Hoo ZH, Candlish J, Teare D. What is an ROC curve? Emerg Med J. 2017;34(6):357–359.
   PubMed Web of Science ®Google Scholar
• G-t M, Y-h W, Yao N, et al. The prognostic role of pretreatment platelet-to-lymphocyte ratio as predictors in patients with colorectal cancer: a meta-analysis. Biomark Med. 2017;11(1):87–97.
   PubMed Web of Science ®Google Scholar
• Kwon HC, Kim SH, Oh SY, et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers. 2012 May;17(3):216–222.
   PubMed Web of Science ®Google Scholar
• Surguladze D, Deevi D, Claros N, et al. Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice. Cancer Res. 2009;69(14):5643–5647.
   PubMed Web of Science ®Google Scholar
• Li Y, Xing C, Wei M, et al. Combining Red Blood Cell Distribution Width (RDW-CV) and CEA Predict Poor Prognosis for Survival Outcomes in Colorectal Cancer. J Cancer. 2019;10(5):1162–1170.
   PubMed Web of Science ®Google Scholar
• Xie X, Yao M, Chen X, et al. Reduced red blood cell count predicts poor survival after surgery in patients with primary liver cancer. Medicine (Baltimore). 2015 Feb;94(8):e577.
   PubMed Web of Science ®Google Scholar
• Hassett MJ, Uno H, Cronin AM, et al. Comparing Survival After Recurrent vs De Novo Stage IV Advanced Breast, Lung, and Colorectal Cancer. 2018;2:2. JNCI Cancer Spectrum.
   Google Scholar
• Mekenkamp LJM, Koopman M, Teerenstra S, et al. Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer. 2010 July 1;103(2):159–164.
   PubMed Web of Science ®Google Scholar
• M-c E-G, Formento J-L, Francoual M, et al. K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy. Clin Cancer Res. 2008;14(15):4830–4835.
   PubMed Web of Science ®Google Scholar
• Freyer G, Rougier P, Bugat R, et al. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups. Br J Cancer. 2000 Aug;83(4):431–437.
   PubMed Web of Science ®Google Scholar
• Ng WWC, Cheung YS, Wong J, et al. A Preliminary Analysis of Combined Liver Resection With New Chemotherapy for Synchronous and Metachronous Colorectal Liver Metastasis. Asian J Surg. 2009 Oct 1;32(4):189–197.
   PubMed Web of Science ®Google Scholar
• Pantaleo MA, Astolfi A, Nannini M, et al. Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. Br J Cancer. 2008 Oct 1;99(10):1729–1734.
   PubMed Web of Science ®Google Scholar
• Bockhorn M, Frilling A, Frühauf NR, et al. Survival of Patients with Synchronous and Metachronous Colorectal Liver Metastases—is there a Difference? J Gastrointestinal Surg. 2008 Aug 1;12(8):1399–1405.
   PubMed Web of Science ®Google Scholar
• Kiely BE. Does Stage at Diagnosis Affect Prognosis of Patients With Stage IV Breast, Lung, and Colorectal Cancers? 2018;2:2. JNCI Cancer Spectrum.
   Google Scholar
• De Jong KP, Stellema R, Karrenbeld A, et al. Clinical relevance of transforming growth factor α, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology. 1998;28(4):971–979.
   PubMed Web of Science ®Google Scholar
• Van Der Wal GE, Gouw ASH, Kamps JAAM, et al. Angiogenesis in Synchronous and Metachronous Colorectal Liver Metastases: the Liver as a Permissive Soil. Ann Surg. 2012;255(1):86–94.
   PubMed Web of Science ®Google Scholar